Iantrek C.Rex System Debuts in Glaucoma Surgery

Iantrek has successfully completed the first commercial cases utilizing its C.Rex micro-interventional system for canal outflow enhancement in glaucoma surgery. This achievement marks the commencement of the company’s pre-launch activities for the innovative C.Rex technology.

C.Rex: A Novel Approach to Canal Outflow Gonio-Intervention

The C.Rex micro-interventional system is an ophthalmic surgical device designed specifically for canal outflow gonio-intervention. Notably, it stands out as the only FDA-registered minimally invasive glaucoma surgery (MIGS) technology capable of performing both excisional circumferential trabeculorhexis and dual-wall canal intervention.

Key Features of the C.Rex System

• Utilizes Nitinol filament technology with memory-shaped super-elasticity.

• Enables a full 360-degree excisional, single- or dual-wall canalotomy.

• Differs from conventional intraocular interventions such as micro-stents, lasers, and non-implantable devices by offering a fully titratable 180- to 360-degree intervention.

According to Iantrek, while conventional intraocular interventions focus only on limited segments of the inner canal wall, the C.Rex portfolio provides a more comprehensive and adjustable approach to enhance trabecular outflow.

Expert Perspectives on the C.Rex Technology

Carol Toris, Professor at the University of Nebraska Medical Center, emphasized the uniqueness of Iantrek’s approach in a company news release:

“All conventional approaches have focused on the trabecular meshwork and the inner canal wall. We have shown empirically and presented our study at ARVO that dual canal intervention can lead to incremental outflow enhancement over single inner wall goniotomy. Iantrek’s approach is uniquely original as it is able to address outflow resistance in the entire canal.”

Dr. Arkadidy Yadgarov, of OMNI Eye Services in Atlanta, became the first U.S. surgeon to utilize the C.Rex technology. He highlighted its advantages:

“There are a lot of trabecular technologies, but this is an interventional breakthrough in non-implantable trabecular outflow surgery. It is one of the most surgically intuitive MIGS technologies, and the only goniotomy system to enable surgical intervention on the entire canal, not just segmentally. The C.Rex offers circumferential excisional goniotomy which is guided, continuous, comprehensive and can reduce resistance in the outer wall.”

Conclusion

The introduction of the C.Rex micro-interventional system represents a significant advancement in MIGS procedures, offering a comprehensive, non-implantable solution for trabecular outflow enhancement. As Iantrek progresses with its pre-launch activities, this groundbreaking technology is poised to reshape the landscape of glaucoma surgery by providing a fully adjustable and intuitive approach to canal-based intervention.